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ABSTRACT
Cardiovascular disease (CVD) remains 
the major cause of death in patients with 
chronic kidney disease (CKD). Left ven-
tricular hypertrophy (LVH) is present in 
75% of patients starting dialysis, sug-
gesting that LVH might be present from 
an early stage of CKD. Few studies have 
addressed the predialysis prevalence of 
LVH. This study evaluated 309 clinically 
stable patients under treatment for at least 
three months at five Brazilian centers. Bio-
chemical profile and inflammatory mark-
ers were assessed. Data were shown as 
mean ± SD. Left ventricular hypertrophy 
was present in 53% of the patients, whose 
mean age was 60 ± 13years. The mean age 
of those without LVH was 55 ± 14 years. 
Diabetes mellitus was the underlying dis-
ease in 35% of the patients in both groups. 
Estimated glomerular filtration rate was 30 
± 11 and 32 ± 12 mL/min for patients with 
and without LVH, respectively (p = 0.19). 
The distribution of patients showed that 
60% of those with LVH were in stage 4. 
Multivariate logistic regression analysis 
indicated the following independent deter-
minants for LVH: age (p < 0.001); calcium 
(p < 0.001); hemoglobin (p < 0.048); and 
diastolic blood pressure (p < 0.001). Systo-
lic blood pressure, lipids, and inflamma-
tory markers showed no correlation with 
LVH. In conclusion, the incidence of LVH 
was high even among patients under con-
servative treatment, and, except for age, 
LVH correlated with reversible factors. 
The need for strictly diagnosing CKD and 
preventing LVH in the predialysis phase is 
emphasized to decrease mortality due to 
CVD in that population. 
Keywords: chronic kidney failure, left 
ventricular hypertrophy, therapy.
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INTRODUCTION
Cardiovascular disease (CVD) is still the 
major cause of death in patients with end-
stage chronic kidney disease (ES-CKD)1, 
with a mortality rate approximately 10 to 
30 times greater than that of the general 
population.2 Heart disease or heart failu-
re are causes of morbidity and mortality 
in that population, and advanced cardio-
myopathy is caused by left ventricular 
hypertrophy (LVH).3-5 
The National Kidney Foundation Task 
Force about CVD in CKD has emphasized 
the high risk of CVD in patients with CKD, 
and has identified LVH and coronary ar-
tery disease as the major targets for inter-
vention.6 Left ventricular hypertrophy is 
an independent predictor of mortality in 
dialysis patients.4,6 Its prevalence is very 
high among patients with ES-CKD star-
ting hemodialysis,7 which suggests that it 
might be present in a large percentage of 
patients with CKD since early stages.
Despite the relevance of that topic, only 
a few studies have been carried out about 
the predialysis prevalence of LVH.1,8 We 
found no report in the literature about 
that topic in the Brazilian population. 
Thus, this study aimed at assessing LVH 
in the CKD population under specialized 
treatment at five nephrological centers in 
Brazil.
 
PATIENTS AND METHODS
This is a multicenter cross-sectional stu-
dy assessing 309 patients with CKD, who 
had been under conservative treatment 
for at least three months. They were selec-
ted at five Brazilian centers specialized in 
CKD (Universidade Federal de São Paulo, 
Universidade de São Paulo, Universidade 
do Estado do Rio de Janeiro, Pontifícia 
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Universidade Católica do Paraná, and Universidade 
Federal de Juiz de Fora) over the year 2005. The stu-
dy comprised clinically stable patients with estimated 
glomerular filtration rate (eGF) ranging from 15 to 60 
mL/min, and aged from 18 to 80 years. The exclusion 
criteria were as follows: acute or chronic infection; 
autoimmune disease; active treatment with steroids or 
immunosuppressors; and malignancy. All participants 
provided written informed consent, which had been 
approved by the Committees on Ethics in Research of 
their respective institutions. 
DATA COLLECTION
Demographical and clinical data were collected in the 
patients’ medical records, and were as follows: age; 
sex; etiology of CKD. The eGF was calculate by use 
of the Cockroft and Gault formula.9
Blood samples were obtained during fasting for 
determining the following: creatinine; urea; lipids; 
hemoglobin; iron; ferritin; transferrin saturation; 
intact parathyroid hormone (reference value, 10–65 
pg/mL); ultra-sensitive C reactive protein (US-CRP) 
(Beckman, Galway, Ireland); and soluble Fas (sFas) 
(detection limit, 8 pg/mL) (OptEIA, PharMingen, San 
Diego, CA, USA). The last two were measured at the 
same laboratory at Hospital do Rim of UNIFESP.   
ECHOCARDIOGRAPHY
Doppler echocardiography was performed in 309 
patients, according to the recommendations of the 
American Society of Echocardiography. Left ventri-
cular systolic function was analyzed through ejection 
fraction calculation with the Teichholz method and 
a lower limit defined as 55%. Left ventricular mass 
(LVM) was estimated with the expression: LVM (g) 
= 08 X {1.04 X [(LVID + IVST + PWT)3- (LVID)3]} 
x 0.6, where: LVM = left ventricular mass; LVID = 
left ventricular inner diameter; IVST = interventricu-
lar septum thickness; PWT = left ventricular poste-
rior wall thickness. Left ventricular mass in relation 
to the patient’s height is left ventricular mass index 
(LVMI) (g/m2), which was considered normal when 
lower than 131 g/m2 in men and lower than 100 g/m2 
in women.12
STATISTICAL ANALYSIS
All variables were expressed as mean ± standard de-
viation, median (variation), and frequency. The pa-
tients were divided into two groups according to the 
presence of LVH. The groups were compared by using 
Mann-Whitney test or Student t test. The distribution 
of categorical variables between groups was analyzed 
by using the chi-square test or Fisher exact test, when 
appropriate. Multiple logistic regression was used to 
identify the factors associated with the presence of 
ventricular hypertrophy. All variables with a signifi-
cance level of at least 0.10 in univariate analysis were 
included in multiple logistic regression analysis. The 
significance level adopted was  p < 0.05. All statistical 
analyses were performed by using SPSS software for 
Windows (SPSS Inc., Chicago, IL, USA).
 
RESULTS
The population studied was 54% male and 64% whi-
te. The prevalence of LVH was 53%, 22% of whom 
were women. Of those without LVH, 40% were wo-
men (Table 1). Diabetes mellitus was present in 35% 
of the patients in both groups. Of those with LVH, 
60% were in stage-4 CKD. Ejection fraction was wi-
thin the normal range for both groups as follows: 1) no 
LVH - women, 67%±10%, and men, 68%±12%; 2) 
with LVH - women, 66%±12%, and men, 67%±10%. 
Only 10% of the patients had systolic dysfunction.
The biochemical profile was as expected, in ac-
cordance with the recommendations of the Brazilian 
Society of Nephrology guidelines.13 Serum calcium 
and phosphate were normal, and the intact para-
thyroid hormone (iPTH) in patients with LVH was 
higher than recommended. Hemoglobin was within 
the normal range. The lipid values were close to nor-
mal, although the LDL fraction was slightly increased 
in the group with LVH. Systolic blood pressure was 
elevated in patients with LVH (Table 2).
The mean values of inflammatory markers were 
elevated (Table 3), but the medians had a great varia-
tion. The CRP showed a tendency towards elevation 
in patients with LVH, unlike sFas, whose values were 
similar and showed a wide variation in both groups.  
Multivariate logistic regression analysis adjusted 
to age indicated the following determinants for LVH: 
calcium; hemoglobin; and diastolic blood pressure 
(Table 4).
 
DISCUSSION
Cardiovascular disease is the major cause of death in 
patients with CKD prior to dialysis.14-16 Left ventri-
cular hypertrophy is present in up to 75% of the pa-
tients starting renal replacement therapy.17 This high 
LVH prevalence helps to keep mortality high and im-
pairs the quality of life of that population.  
Most of the patients assessed in this study were in 
stage 4 of CKD. Most patients with LVH were ma-
les; women did not show the same LVH prevalence, 
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especially in stage 3. Diabetes is considered an impor-
tant mediator of CVD, but that did not apply to the 
patients of the present study, in which the prevalence 
was the same in both groups.
The parameters analyzed have shown that the 
patients were clinically stable. The treatment of dys-
lipidemia was based on diet and/or medications for 
reaching the target recommended by the guidelines of 
the Brazilian Society of Nephrology,13 and the lipid 
profile was very satisfactory. Those data support the 
information that lipids do not play a central role in 
the development of CVD in that population. 4
Inflammatory markers have been suggested to be 
good predictors of CV events in patients with ES-CKD. 
This is particularly true for serum CRP levels.18-20 Fas 
is a membrane protein that belongs to the family of 
tumor necrosis factor receptors;21 sFas accumulates in 
serum as renal disease progresses.22 Recently, sFas has 
been reported to be an independent predictive factor 
of coronary disease in patients on chronic hemodialy-
sis.21 Although CRP tends to be higher in patients wi-
th LVH, the values have shown a wide variation, and 
the difference was not statistically significant. The 
sFas measurement showed no difference between the 
Table 1  CHARACTERISTICS OF THE PATIENTS WITH CHRONIC KIDNEY DISEASE (CKD).
   
    Patients Female  Male CKD stage  DM  
    n (%) n (%) n (%) 
With LVH    164 (53%) 37 (22%)  127 (78%) 3 = 40% 35%
       4 = 60% 
No LVH   145(47%)  58 (40%)  87 (60%)  3 = 49% 35%
       4 = 51%
DM = diabetes mellitus; LVH = left ventricular hypertrophy .
Table 2 AGE AND LABORATORY CHARACTERISTICS OF THE POPULATION STUDIED (n = 309).
  No LVH With LVH  p
  n = 145 n = 164
Age (years) a 55 ± 14 60 ± 13 < 0.01
eGF mL/min 32 ± 12 30 ± 11 0.19
Ca mg/dL  9.8 ± 0.9 9.3 ± 0.9 < 0.01
P mg/dL  3.8 ± 0.8 4 ± 0.9 0.04
iPTH pg/m  146 ± 111 198 ±164 < 0.01
Hb g/dL  12.8 ± 1.8 12.3 ± 1.8 0.04
Iron µg/dL  80 ± 25 77 ± 25 0.46
TSat %  29 ± 8 27 ± 7 0.21
Ferritin ng/mL 160 ± 181 127 ± 129 0.1
Cholesterol mg/dL 200 ± 48 203 ± 44 0.65
Trig mg/dL  173 ± 162 150 ± 64 0.12
SBP mmHg 133 ± 23 143 ± 27 < 0.01
DBP mmHg 78 ± 12 83 ± 16 < 0.01
Glucose mg/dL 125 ± 68 121± 64 0.68
a Mean ± SD; Ca = calcium; SBP = systolic blood pressure; eGF = estimated glomerular fi ltration rate; Hb = hemoglobin; 
iPTH = intact parathyroid hormone; LVH = left ventricular hypertrophy; P = phosphate; Trig = triglycerides; TSat = transferrin saturation; 
DBP = diastolic blood pressure
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groups with and without LVH. All those data have 
suggested that, at least by using those markers, clini-
cally stable patients before dialysis have not shown 
inflammation as a key mediator of LVH.
Strict control of blood pressure (BP) is known to 
be one of the best practices to prevent LVH.23 Of all 
patients, 49% showed high systolic BP levels, and 
34% showed high diastolic BP levels. Of those with 
LVH, 54% and 41% had increased systolic and dias-
tolic BP levels, respectively. In addition, diastolic BP 
was an independent determinant of LVH. This is a 
worrying result, because BP control should no be a di-
fficult target to be reached, at least for most patients, 
considering the existing therapeutic armamentarium. 
We insist in the importance of strict BP control as an 
efficient measure for preventing both LVH and CKD 
progression.24
Recent studies have shown that hemoglobin nor-
malization does not benefit that population.25,26 On 
the other hand, anemia is known to be an important 
promoting factor of LVH.27 Our data have shown 
that hemoglobin values were within the normal range 
in the stage-4 population studied. However, hemoglo-
bin was an independent determinant factor of LVH. 
Normal hemoglobin values (data not shown) were 
observed in 82% of the patients, in accordance with 
the recommendation of the guidelines.28 On the other 
hand, 18% of the patients had hemoglobin levels be-
low 11g/dL. Such results indicate the importance of 
an adequate evaluation and treatment of anemia in 
that population, since it is an important factor related 
to uremia that also contributes to LVH.27,29
Calcium and phosphate levels were within the nor-
mal range, but were different between the groups with 
and without LVH. Intact parathyroid hormone was 
also elevated in patients with LVH and was different 
from that in the group with no LVH. A correlation be-
tween mineral metabolism, hyperparathyroidism, and 
LVH has been suggested, although its mechanism has 
not yet been totally understood.30 Hyperphosphatemia 
is recognized as a risk factor for CV mortality in the 
population with ES-CKD.31 The mechanism linking 
hyperphosphatemia with CV mortality in patients 
on renal replacement therapy is not completely kno-
wn; however, recent data have suggested that hyper-
phosphatemia could have a deleterious effect, causing 
LVH.32,33 Gomes et als. have reported that phosphate 
levels, even when within the normal range, have as-
sociated with a PTH elevation in patients with CKD 
prior to dialysis.34 The present data have suggested that 
before dialysis those factors could be involved in deter-
mining LVH. Such data confirm the need for further 
studies on the correlation between changes in mineral 
metabolism and LVH since early CKD stages.
Table 3 INFLAMMATORY MARKERS
   No LVH With LVH p
CRP mg/L (n) 130 148
Median (min-max) 0.32 (0.01-12.8)  0.46 (0.016- 6)  0.16
   0.13-0.68 0.19-1.09 
25-75 Percentile 
sFas pg/mL (n) 97 101
Median (min-max) 2227 (124-2613) 1560 (108 - 3592) 0.85
   705-2193 547-2410  
25-75 Percentile 
CRP = C-reactive protein; LVH= left ventricular hypertrophy; sFas = soluble Fas.
Table 4 MULTIVARIATE LOGISTIC REGRESSION ANALYSIS
Variables  ß Coeffi cient  95% CI p
Calcium (mg/dL) 0.54 0.39 – 0.76 < 0.01
Hb (g/dL)   0.84 0.71 – 0.99 0.04
DBP (mmHg) 1.05 1.02 – 1.07 < 0.001
DBP = diastolic blood pressure; Hb = hemoglobin; CI = confi dence interval.
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Coronary disease and LVH in patients with ES-
CKD have been recognized as atypical presentations 
of heart disease.23 The present study confirms that 
statement, adding that approximately 40% of the 
patients with LVH have stage-3 CKD, emphasizing 
the hypothesis that that alteration occurs early. It is 
worth noting that the literature on that topic focu-
ses on patients with CVD and no renal disease, and 
guidelines about CVD in patients with CKD are ba-
sed on opinions, not on evidence, showing the lack 
of information in that area.23 The first step to reverse 
that is identifying and quantifying the magnitude of 
the problem. The challenge faced by physicians is to 
identify CKD and treat it aggressively.
In conclusion, in our study, the incidence of LVH 
was high even in a group of patients undergoing spe-
cialized treatment. The results have shown that some 
determinants are reversible factors. Thus, it is para-
mount that preventive measures for LVH are adopted 
and evaluated in regard to their efficacy in preventing 
LVH, to optimize the treatment of CKD as a whole. 
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